bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
092-10-0020

Order Name:
CYP2C9 genotyping (2 SNP; Fast track)

 
Useful For:
Identifying patients who may be at risk for altered metabolism of drugs that are modified by CYP2C9. Predicting drug response to NSAID, Phenytoin.
 
Methodology:
Real-time PCR
 
AliasesName:
CYP2C9
pgx
Pharmacogenetics
Pharmacogenomics
 
 
 
Test Code:
092-10-0020

Order Name:
CYP2C9 genotyping (2 SNP; Fast track)

 
Collection Specimen Or Container:
Blood/ K3 EDTA (K3E) (Lavender Top) 3 mL, 1 tube
 
Specimen Testing Type:
Whole blood, K3 EDTA (K3E) (Lavender Top) 3 mL, 1 tube, minimum volume 1.5 ml
 
Sub Mission Container:
Original tube
 
Rejection Criteria:
Use heparin as anticoagulant, Severe clotted specimen will be reject.
 
Specimen Stabillity:
Specimen Type Temperature Time
EDTA Whole Blood Refrigerated, 2oC to 8oC 7 days
 
 
 
Test Code:
092-10-0020

Order Name:
CYP2C9 genotyping (2 SNP; Fast track)

 
Method detail:
Real-time PCR
 
Schedule:
Test Daily
 
Turnaround Time:
Received specimen to report within 3 days
 
Performing Location:
Research and Development, Tel. 14252
 
Specimen Retention Time:
3 months
 
 
 
Test Code:
092-10-0020

Order Name:
CYP2C9 genotyping (2 SNP; Fast track)

 
 
Clinical Information:
CYP2C9 is an important drug metabolizing enzyme that catalyzes the biotransformation of many other clinically useful drugs including phenytoin, angiotensin II blockers, non-steroidal anti-inflammatory drugs, the alkylating anticancer prodrugs. This test identifies three common alleles (*1, *2, *3) by Real-time PCR. The CYP2C9 genotyping (2 SNP; Fast track) test covers two known no functional alleles. 
 
Clinical Reference:
  1. Lima JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2020 Aug 8. doi: 10.1002/cpt.2015.
  2. Pratt VM, et al. Recommendations for Clinical CYP2C9 Genotyping Allele Selection: A Joint Recommendation of the Association for Molecular Pathology and College of American Pathologists.J Mol Diagn. 2019 Sep;21(5):746-755. doi: 10.1016/j.jmoldx.2019.04.003. Epub 2019 May 8.